**Title:** Indian Drugmakers Challenge Novo Nordisk’s Semaglutide Patent
**Meta Description:** Two Indian firms are suing Novo Nordisk over semaglutide, anticipating a lucrative market for weight-loss drugs as the patent nears expiration in 2026.
**URL Slug:** indian-drugmakers-novo-nordisk-semaglutide-patent
**Headline:** Indian Drugmakers File Lawsuits Against Novo Nordisk Over Semaglutide Patent
In a significant legal move, two Indian pharmaceutical companies have initiated lawsuits against Danish drugmaker Novo Nordisk concerning its highly successful weight-loss medication, semaglutide. With the patent for this drug set to expire in India in March 2026, the timing of these lawsuits raises questions about the motivations behind them.
Recently, Natco Pharma filed six lawsuits in the Delhi High Court against Novo Nordisk regarding its well-known anti-obesity drug, semaglutide, marketed as Wegovy in India. The Hyderabad-based company argues that its versions of semaglutide and the associated delivery device do not infringe on Novo Nordisk’s patents, allowing them to potentially launch their products before the patent officially expires. Natco had previously sent notices to Novo Nordisk on June 30 but reportedly received no response. The court addressed the matter on August 20, suggesting both parties engage in pre-suit mediation to seek an amicable resolution.
In a related development, Dr. Reddy’s Laboratories, also based in Hyderabad, has challenged the validity of Novo Nordisk’s second patent on semaglutide, claiming it lacks novelty. This patent is also set to expire in March, paving the way for a surge of affordable generic alternatives. Following this challenge, Novo Nordisk filed a patent infringement lawsuit against Dr. Reddy’s.
The urgency behind these legal actions stems from the soaring global demand for medications that mimic hormones regulating hunger and insulin, which can facilitate weight loss of 15-23% over six months. Semaglutide injections, marketed under the brands Wegovy and Ozempic, have propelled Novo Nordisk into a dominant position in the pharmaceutical market, generating over $25 billion in sales last year. The company launched Wegovy in India in July, following competitor Eli Lilly’s introduction of Mounjaro (tirzepatide) in March. Both firms are racing to capture significant market share before generics flood the market post-patent expiration. With over 254 million obese individuals and more than 100 million diabetics in India, the market potential is substantial.
Analysts predict that the weight-loss drug market could expand to ₹8,000 to ₹10,000 crore within the next two to three years, marking it as one of the largest emerging categories in the Indian pharmaceutical sector. Despite the anticipated drop in prices by over 80% with the introduction of generics, nearly every major generic drug manufacturer in India, including Sun Pharmaceutical Industries, Cipla, Lupin, Zydus, Eris Lifesciences, and Mankind Pharma, is preparing to launch their versions of the drug next year, with some aiming for first-mover advantage.
In summary, the legal actions taken by Natco Pharma and Dr. Reddy’s Laboratories against Novo Nordisk highlight the competitive landscape of the weight-loss drug market in India, as companies position themselves ahead of the impending patent expiration.
**FAQ:**
**Q: Why are Indian drugmakers suing Novo Nordisk?**
A: Indian drugmakers are suing Novo Nordisk to challenge its patents on semaglutide, anticipating a lucrative market for weight-loss drugs as the patent nears expiration in 2026.